Search

News Comparison of EHL Products in the Treatment of Hemophilia A –⁠ Pharmacoeconomic Analysis

In the work presented below, whose results were recently published, a model combining pharmacokinetic and pharmacodynamic data was developed. With its help, the authors tried to compare the bleeding rates in hemophiliacs treated with various EHL products. At the same time, they focused on the cost-effectiveness of this treatment.

Source: Hemophilia with Movement 21. 5. 2021

News Position of Generic Drugs in Oncology: What Are Their Main Advantages?

Generics –⁠ as is well known –⁠ are products containing the same active substance as the original medicinal product, which can enter the market after the patent protection of the original drug has expired. They are applied in various medical fields, including oncology. The main goal of producing generics is to improve the accessibility of treatment for a wide range of patients while maintaining the safety and effectiveness of the therapy.

Source: Oncological Treatment 15. 9. 2021

News Impact of Alpha-1 Antitrypsin Deficiency on Quality of Life and Mental Health of Patients

The clinical manifestation of alpha-1 antitrypsin deficiency and its impact on quality of life are highly heterogeneous. This contribution by pulmonologist Robert Sandhaus summarizes interesting findings from studies on the quality of life of patients with this disease and the factors influencing it.

Source: Deficiency of Alpha-1-Antitrypsin 3. 11. 2020

News Can alpha-1-antitrypsin deficiency affect severity and higher mortality in COVID-19 patients?

Alpha-1-antitrypsin (AAT) deficiency is commonly found in the European population. The most cases are recorded in countries with the highest COVID-19 mortality rates. Are there direct correlations?

Source: Deficiency of Alpha-1-Antitrypsin 12. 4. 2021

News Efficacy of Brigatinib in Patients with Metastatic NSCLC −⁠ Real-World Clinical Data

The journal Lung Cancer published the results of a retrospective analysis of the efficacy of brigatinib in patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who participated in a European early access treatment program.

Source: Non-Small Cell Lung Cancer 29. 11. 2021

News Curative Potential of Neoadjuvant Denosumab in the Treatment of Giant Cell Spinal Tumor? A Case Study

Portuguese authors present a case study of a young woman diagnosed with a giant cell spinal tumor who achieved complete histological remission following denosumab treatment.

Source: Prevention of Bone Events 9. 4. 2022

News How does the level of uric acid affect the incidence of cardiorenal events in patients with T2DM and CVD?

One of the post hoc analyses of the well-known EMPA-REG OUTCOME study provided data on the relationship between uric acid levels and the incidence of cardiorenal events in type 2 diabetics with existing cardiovascular disease.

Source: Diabetes 21. 7. 2023

News View on the Treatment of Rheumatoid Arthritis with Baricitinib Using the NNT Indicator

Clinical parameters assessed by patients themselves are an important tool in evaluating the effectiveness of new drugs and are particularly significant in the evaluation of treatments for chronic painful conditions, such as rheumatoid arthritis (RA). An analysis of clinical trial results presented at the European Rheumatology e-Congress in June 2020 focused on the effectiveness of the Janus kinase inhibitor baricitinib on parameters assessed directly by patients. Effectiveness was analyzed using the NNT indicator.

Source: Biological Treatment 30. 11. 2020

News Excellent effect of sotorasib in a higher line of treatment in a patient with NSCLC with G12C mutation of KRAS –⁠ a case study

We present a case study of an elderly patient with non-small cell lung cancer (NSCLC) treated with the selective KRASG12C inhibitor sotorasib in the 5th line of oncological treatment, but with a very exceptional effect.

Source: Lung Cancer 30. 10. 2024

News Should patients with primary immunodeficiencies fear COVID-19 more than the general population?

The body fights the new SARS-CoV-2 virus, which causes COVID-19, in a similar way to other viral infections -⁠ by intensely engaging the immune system. But what if it's weakened?

Source: Primary and Secondary Immunodeficiencies 7. 5. 2020

News Analysis of Data from the EMPEROR-Preserved Study Revealed Whether Blood Pressure Affects the Effectiveness of Empagliflozin in Patients with Heart Failure with Preserved Ejection Fraction

Hypertension is among the most common etiological factors of heart failure with preserved ejection fraction (HFpEF), where pressure overload of the left ventricle leads to its eccentric hypertrophy and diastolic dysfunction. According to recent study results, empagliflozin significantly reduces the risk of cardiovascular (CV) complications in patients with HFpEF. The EMPEROR-Preserved sub-analysis further examined the impact of baseline systolic blood pressure (sBP) on treatment outcomes and patient prognosis.

Source: Heart Failure 19. 6. 2023

News Dust Mite Allergy and the Risk of Sleep-Disordered Breathing

New York authors in their recently published retrospective analysis tested the hypothesis that individuals with allergic rhinitis caused by dust mite allergy have an increased risk of breathing disorders during the REM phase of sleep, based on objective polysomnography evaluation.

Source: Dust Mite Allergy 29. 10. 2021

News Tool for Predicting Cardiometabolic Risk in Young Patients with Psychotic Disorder

A study describing the development and validation of an algorithm for predicting cardiometabolic risk in patients with psychotic disorder, PsyMetRiC (Psychosis Metabolic Risk Calculator), was recently published in Lancet Psychiatry. British scientists have created a tool to estimate the risk of developing metabolic syndrome over the next 6 years, serving as a predictor of cardiovascular morbidity and mortality in young people with psychosis aged 16–35 years.

Source: Modern Treatment of Schizophrenia 13. 12. 2022

Články časopisu Exogenous allergic alveolitis in automobile industry –⁠ case report

Author of the article: Kunová Magdalena, Machartová Vendulka, Bejčková Hana Source: Pracovní lékařství | 1/2014 2. 4. 2014

News Chemoimmunotherapy in the Treatment of Breast Cancer −⁠ Final Results of the IMpassion130 Study

According to international recommendations, treatment with the immune checkpoint inhibitor atezolizumab in combination with the cytostatic nab-paclitaxel is used for patients with locally advanced or metastatic breast cancer where PD-L1 protein expression is detected on the surface of tumor-infiltrating immune cells (IC). The final results regarding overall survival and long-term safety of this treatment in patients who participated in the registration study IMpassion130 were presented at this year's European Society for Medical Oncology (ESMO) congress, which was held virtually due to circumstances.

Source: Breast Carcinoma 25. 10. 2020